 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
51 News |  |
- | remetinostat (SHP-141) / Medivir
Journal, Epigenetic controller: Nitrilase mediated mild hydrolysis of a carbon-14 nitrile for the radiosynthesis of 4-(7-hydroxycarbamoyl-[1- C-heptanoyl]-oxy)-benzoic acid methyl ester, [ C]-SHP-141: a novel class I/II histone deacetylase (HDAC) inhibitor. (Pubmed Central) - Jun 20, 2023
The final step involved deprotection of the benzyloxy group using catalytic hydrogenation to facilitate the release of the hydroxamic acid without cleaving the phenoxy ester. [ C]-SHP-141 was isolated with a radiochemical purity of 90% and a specific activity of 190 ?Ci/mg from four radiochemical steps starting from potassium [ C]-cyanide in a radiochemical yield of 45%.
- | patidegib topical (IPI-926 topical) / Bridge Biotherap, LEO Pharma
Journal: Recent advances in chemical composition and transdermal delivery systems for topical bio-actives in skin cancer. (Pubmed Central) - Sep 4, 2022
In particular, significant studies have been made, including modification of bio-actives, permeability enhancers, incorporation of advanced nano and microcarriers, and physical enhancement devices. This critical review summarizes the advancement in the chemical composition of bioactives used in skin cancer, such as sinecatechins, BIL-010t, patidegib, gingerol, curcumin, remetinostat, epigallocatechin-3-gallate, etc. Furthermore, this review, specifically addresses the progress in transdermal delivery systems for melanoma and non-melanoma cancer therapy, emphasizing advances in physical and chemical penetration enhancement and nanocarrier-assisted transdermal systems.
- || remetinostat (SHP-141) / Medivir
Clinical, P2 data, Journal: Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma. (Pubmed Central) - Apr 5, 2022
The HDAC inhibitor remetinostat is a well-tolerated and effective topical treatment for reducing BCC disease burden in a clinically significant manner. This provides in-human validation of HDAC inhibitors as a therapy for BCC.
- | remetinostat (SHP-141) / Medivir
Journal, Epigenetic controller: Treatment of Cutaneous Squamous Cell Carcinoma With the Topical Histone Deacetylase Inhibitor Remetinostat. (Pubmed Central) - Mar 26, 2022
This provides in-human validation of HDAC inhibitors as a therapy for BCC. No abstract available
- || remetinostat (SHP-141) / Medivir
Medivir strengthens the business development potential of remetinostat through renegotiated multi-party agreement https://t.co/g6gWAfYkbG (Twitter) - Aug 15, 2021
- || remetinostat (SHP-141) / Medivir
Trial completion: Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer (clinicaltrials.gov) - Jun 8, 2021
P2, N=30, Completed, Sponsor: Kavita Sarin
No abstract available Active, not recruiting --> Completed
- remetinostat (SHP-141) / Medivir
[VIRTUAL] Is topical remetinostat gel an effective and safe treatment for basal cell carcinoma? Results of a phase 2, open label, single arm trial () - Feb 12, 2021 - Abstract #SID2021SID_468;
Remetinostat, a topical pan-HDAC inhibitor, is a safe and effective topical treatment for BCC, reducing disease burden in a clinically significant manner. Our results provide the first in-human validation of HDAC inhibitors as a potential therapeutic.
- | remetinostat (SHP-141) / Medivir
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Feb 3, 2021
P2, N=4, Terminated, Sponsor: Kavita Sarin
Our results provide the first in-human validation of HDAC inhibitors as a potential therapeutic. N=40 --> 4 | Trial completion date: Oct 2021 --> Jan 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2021 --> May 2020; The available study medication reached expiry (logistics).
- | remetinostat (SHP-141) / Medivir
Enrollment closed, Enrollment change: Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Nov 23, 2020
P2, N=40, Active, not recruiting, Sponsor: Kavita Sarin
N=40 --> 4 | Trial completion date: Oct 2021 --> Jan 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2021 --> May 2020; The available study medication reached expiry (logistics). Recruiting --> Active, not recruiting | N=30 --> 40
- | remetinostat (SHP-141) / Medivir
Enrollment closed: Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer (clinicaltrials.gov) - Jun 17, 2020
P2, N=30, Active, not recruiting, Sponsor: Kavita Sarin
Recruiting --> Active, not recruiting | N=30 --> 40 Recruiting --> Active, not recruiting
- | remetinostat (SHP-141) / Medivir
Enrollment open: Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Dec 9, 2019
P2, N=30, Recruiting, Sponsor: Kavita Sarin
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | remetinostat (SHP-141) / Medivir
Trial completion date, Trial primary completion date: Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer (clinicaltrials.gov) - Sep 19, 2019
P2, N=30, Recruiting, Sponsor: Kavita Sarin
Not yet recruiting --> Recruiting Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Jun 2020
- | remetinostat (SHP-141) / Medivir
Trial completion date, Trial initiation date, Trial primary completion date: Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Jun 23, 2019
P2, N=30, Not yet recruiting, Sponsor: Kavita Sarin
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Jun 2020 Trial completion date: Nov 2022 --> Oct 2021 | Initiation date: May 2019 --> Oct 2019 | Trial primary completion date: May 2022 --> Apr 2021
- | remetinostat (SHP-141) / Medivir
New P2 trial: Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Mar 15, 2019
P2, N=30, Not yet recruiting, Sponsor: Kavita Sarin
- | remetinostat (SHP-141) / Medivir
Enrollment open: Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer (clinicaltrials.gov) - Jul 12, 2018
P2, N=30, Recruiting, Sponsor: Kavita Sarin
Trial completion date: Nov 2022 --> Oct 2021 | Initiation date: May 2019 --> Oct 2019 | Trial primary completion date: May 2022 --> Apr 2021 Not yet recruiting --> Recruiting
- | remetinostat (SHP-141) / Medivir
Trial initiation date, Trial primary completion date: Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer (clinicaltrials.gov) - Jan 23, 2018
P2, N=30, Not yet recruiting, Sponsor: Kavita Sarin
Not yet recruiting --> Recruiting Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jun 2019
- | remetinostat (SHP-141) / Medivir
Trial initiation date: Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer (clinicaltrials.gov) - Sep 6, 2017
P2, N=30, Not yet recruiting, Sponsor: Kavita Sarin
Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jun 2019 Initiation date: Aug 2017 --> Jan 2018
- | remetinostat (SHP-141) / Medivir
New P2 trial: Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer (clinicaltrials.gov) - Jun 8, 2017
P2, N=30, Not yet recruiting, Sponsor: Kavita Sarin
- || remetinostat (SHP-141) / Medivir
Trial primary completion date, Epigenetic controller: Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Oct 20, 2016
P2, N=60, Active, not recruiting, Sponsor: TetraLogic Pharmaceuticals
Initiation date: Aug 2017 --> Jan 2018 Trial primary completion date: May 2016 --> Oct 2016
- | remetinostat (SHP-141) / Medivir
Trial initiation date, Trial primary completion date, Epigenetic controller: Safety and Efficacy Study of SHAPE Gel in Alopecia Areata (clinicaltrials.gov) - Oct 20, 2016
P2, N=40, Not yet recruiting, Sponsor: TetraLogic Pharmaceuticals
Trial primary completion date: May 2016 --> Oct 2016 Initiation date: Feb 2016 --> Feb 2017 | Trial primary completion date: Nov 2016 --> Aug 2017
- ||| remetinostat (SHP-141) / Medivir
Enrollment closed, Epigenetic controller: Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Feb 4, 2016
P2, N=60, Active, not recruiting, Sponsor: TetraLogic Pharmaceuticals
Initiation date: Feb 2016 --> Feb 2017 | Trial primary completion date: Nov 2016 --> Aug 2017 Recruiting --> Active, not recruiting
- | remetinostat (SHP-141) / Medivir
New P2 trial, Epigenetic controller: Safety and Efficacy Study of SHAPE Gel in Alopecia Areata (clinicaltrials.gov) - Dec 21, 2015
P2, N=40, Not yet recruiting, Sponsor: TetraLogic Pharmaceuticals
- |||| remetinostat (SHP-141) / Medivir
Enrollment open, Epigenetic controller: Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Jan 13, 2015
P2, N=60, Recruiting, Sponsor: TetraLogic Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| remetinostat (SHP-141) / Medivir
New P2 trial, Epigenetic controller: Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Aug 12, 2014
P2, N=60, Not yet recruiting, Sponsor: TetraLogic Pharmaceuticals
- | remetinostat (SHP-141) / Medivir
Trial completion, Enrollment change, Trial primary completion date, Epigenetic controller: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) (clinicaltrials.gov) - Aug 11, 2014
P1, N=18, Completed, Sponsor: TetraLogic Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=48 --> 18 | Trial primary completion date: Mar 2014 --> Sep 2013
- remetinostat (SHP-141) / Medivir
Enrollment closed, Epigenetic controller: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) (clinicaltrials.gov) - Feb 11, 2014
P1, N=48, Active, not recruiting, Sponsor: Shape Pharmaceuticals, Inc.
Active, not recruiting --> Completed | N=48 --> 18 | Trial primary completion date: Mar 2014 --> Sep 2013 Recruiting --> Active, not recruiting
- | remetinostat (SHP-141) / Medivir
New P1 trial, Epigenetic controller: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) (clinicaltrials.gov) - Sep 12, 2011
P1, N=48, Active, not recruiting, Sponsor: Shape Pharmaceuticals, Inc.